DarioHealth, a global digital therapeutics company, has announced the results of two new clinical studies presented at the 16th International Conference on Advanced Technologies and Treatments for Diabetes (ATTD) 2023 in Berlin.
One of the studies demonstrated improved clinical outcomes in users with Type 2 diabetes and provided further analysis to understand the mediating effects of live human coaching and digital interventions across the Dario user journey.
The second study demonstrated Dario's ability to reduce hypoglycemic events in older adults with a digital chronic condition management solution.
The Role of Coaching in a Digital-First Chronic Condition Management Solution
To better understand the impact of human coaching in a digital journey, Dario's research team examined the data from 712 higher-risk members engaged in Dario's diabetes solution to manage Type 2 diabetes, split into two groups: those members engaged with a coach and a matched group of those who did not interact with a coach at all.
Across both groups, the study demonstrated clinically significant reductions in monthly average blood glucose during a 12-month period: an 18% reduction in average blood glucose for those engaged with a coach and 11% for those who did not engage with a coach.
Further analysis yielded insights on the meditating effects of blood glucose monitoring and digital engagement and overall, the data suggest that coaching can be used to optimize engagement in a more targeted fashion to achieve improved clinical outcomes.
This research provides evidence that the use of coaching in a digital health solution may have a positive impact on behaviours and outcomes and, when deployed in a targeted and intelligent manner, can play a significant role in supporting more effective personalized support.
Reducing Hypoglycemic Events in Older Members
Dario examined the data from 2,844 users aged 67 and older living with Type 1 or Type 2 diabetes over a period of one year.
The data showed a significant reduction of both level 1 and level 2 hypoglycemic events through the use of digital engagement:
Level 1 hypoglycemic events, or blood glucose readings less than 70 mg/dL, were reduced by 31% after 6 months with results sustained through 12 months of engagement.
Level 2 hypoglycemic events, or blood glucose readings less than 54 mg/dL, were reduced by 53% after 6 months with results sustained through 12 months of engagement.
Click here to read the original news story.
Looking for expert insights in Digital Therapeutics (DTx)? Join the HealthXL Masterclass on ‘How Germany Channeled Digital Health Apps into its Health System’ on 14th March. Click here to Request to Join.